EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phenethylamine-Derived β-Lactam Derivatives as Antibacterial Leads against Respiratory Pathogens: In Vitro Evaluation, Cytotoxicity Profiling, and In Silico Insights

Merve Yildirim, Elif Aksakal, Taha Yasin Bayram, Eda Irmak, Harun Gun, Bunyamin Ozgeris, Arzu Gormez

ACS Omega · 12.11.2026

DOI: 10.1021/acsomega.6c06993 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Omega, online erschienen am 12.11.2026. Verfasst von Merve Yildirim und 6 weiteren Autor:innen. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Secondary pulmonary bacterial infections represent a severe clinical complication in lung cancer management, necessitating effective antibacterial strategies. In this study, a series of phenethylamine-derived imines (1–6) and their cyclized β-lactam derivatives (7–12) were systematically evaluated as prospective antibacterial leads against respiratory pathogens (Klebsiella pneumoniae and Streptococcus pneumoniae), alongside cytotoxicity profiling in A549 human lung cells. Phenotypic antibacterial assays showed that open-chain imine precursors (1–6) had no discernible activity, whereas core cyclization into β-lactam derivatives (7–12) conferred antibacterial activity (MIC: 12.5–50 μM), including activity against K. pneumoniae, which showed no inhibition zone with ampicillin. Compounds 7 and 11 had the lowest MICs against K. pneumoniae (12.5 μM). Comparing MIC values with A549 cytotoxicity gave an in vitro selectivity index (SI) of >16 for compound 7 against K. pneumoniae. This is a censored lower bound (A549 IC50 > 200 μM) that reflects low cytotoxicity in a lung cell line and does not indicate cancer selectivity. Preliminary molecular docking against bacterial penicillin-binding proteins (PBPs) and human MDM2 gave scores that differed little among compounds and did not follow the MIC values, so they are treated here as exploratory only. Overall, these findings identify phenethylamine-derived β-lactams as a scaffold for antibacterial lead development that warrants further mechanistic investigation and testing in noncancerous lung cells.

Zitieren

APA

Yildirim, M., Aksakal, E., Bayram, T. Y., Irmak, E., Gun, H., Ozgeris, B., & Gormez, A. (2026). Phenethylamine-Derived β-Lactam Derivatives as Antibacterial Leads against Respiratory Pathogens: In Vitro Evaluation, Cytotoxicity Profiling, and In Silico Insights. ACS Omega. https://doi.org/10.1021/acsomega.6c06993

Vancouver

Yildirim M, Aksakal E, Bayram TY, Irmak E, Gun H, Ozgeris B, et al. Phenethylamine-Derived β-Lactam Derivatives as Antibacterial Leads against Respiratory Pathogens: In Vitro Evaluation, Cytotoxicity Profiling, and In Silico Insights. ACS Omega. 2026. doi:10.1021/acsomega.6c06993

BibTeX
@article{Yildirim2026,
  author = {Yildirim, Merve and Aksakal, Elif and Bayram, Taha Yasin and Irmak, Eda and Gun, Harun and Ozgeris, Bunyamin and Gormez, Arzu},
  title = {Phenethylamine-Derived β-Lactam Derivatives as Antibacterial Leads against Respiratory Pathogens: In Vitro Evaluation, Cytotoxicity Profiling, and In Silico Insights},
  journal = {ACS Omega},
  year = {2026},
  doi = {10.1021/acsomega.6c06993}
}
Kostenlos starten →